drugs
CTNJ: Public Option Discussion Moves Forward
Connecticut healthcare insurance premiums are expensive, pricing out too many individuals and businesses. This session, lawmakers are considering whether to create a public insurance option, accountable to government, to bring down costs. Yesterday, CT News Junkie’s second public policy forum at the Capitol explored the issue with policymakers and experts. Hear the discussion
Read MorePublic Option Forum – high expectations, big challenges
Legislators were warned that ideas that sound simple are rarely that easy at last week’s forum on building a public option to bring down CT’s high health insurance premiums. The forum by the Insurance and Human Services Committees brought in national experts to explore the concept. The idea is to create a non-profit, publicly-accountable insurance…
Read MoreCT Medicaid’s managed fee-for-service model saved $300 million last year
Updated 2/19/2019 We got very good news on Medicaid spending, again, at last week’s MAPOC meeting. Per member costs were down 2% from 2016 to last year, even despite hospital rate increases, saving taxpayers $300 million. The state’s share of Medicaid has barely budged since 2014, despite huge enrollment increases. CT remains behind other states…
Read MoreAnother reason to be glad HUSKY fired managed care
New favorite quote – “If you have a dumb incentive system, you get dumb outcomes.” Charlie Munger, quoted by 46brooklyn A new analysis by 46brooklyn highlights the extra costs to Medicaid managed care programs of drug industry middlemen. Ohio’s Medicaid program pays $224 extra in markups to Pharmacy Benefit Managers (PBMs) hired by managed care…
Read MoreLidocaine patch leads CT Medicaid drug spending
According to the latest data visualization from 46brooklyn, CT’s Medicaid program is spending a lot on lidocaine patches. Lidocaine is a local anesthetic that relieves nerve pain. Over the last three available quarters (Q3,4 2017 and Q1 2018), Lidocaine patches have topped CT Medicaid’s list of 25 most costly medications. This medication isn’t on the…
Read MoreRash of New Haven overdoses the latest in a growing CT problem
The New Haven Register is reporting that there’ve been 80 overdoses on the Green in the last two days. Two patients overdosed three times each Wednesday. It was ongoing earlier this afternoon. DPH delivered 50 more doses of naloxone to city first responders and is facilitating communications between city agencies. DMHAS has engaged mental health…
Read MoreGood news – FDA committee reviewing lots more antibiotics
The best news from this week’s FDA Anti-Microbial Advisory Committee meeting was that there are a lot of meetings. A busy committee means that they have more antibiotics to review. The race against drug-resistant superbugs has reduced incentives for drug companies to develop antibiotics. These drugs cost as much to develop as others but are…
Read MoreNew site compares Medicaid drug prices across states and overall drug price trends
There is a lot of drug pricing data available publicly but it is hard to synthesize. 46brooklyn has solved this problem by merging that data and putting it into understandable graphs and maps. The Medicaid drug pricing heat map is fascinating. Using CMS data to compare what state Medicaid programs are spending on prescriptions with…
Read MoreLast year CT physicians and teaching hospitals received $34 million from manufacturers and GPOs
New data shows that 21 teaching hospitals and 13,310 physicians in CT received $34 million in payments and gifts from drug and device manufacturers and Group Purchasing Organizations (GPOs) last year. Open Payments, the searchable federal data source, was created by the Affordable Care Act which requires that manufacturers disclose payments to physicians and teaching…
Read MoreICER to report on unjustified drug price increases
Early next year, the nonprofit Institute for Clinical and Economic Review (ICER) will issue its first report on US drug price increases that are not supported by clinical evidence. ICER is a leader in assessing the value of medical treatments, including medications. ICER’s benchmark price ranges for new drugs have been used by Medicaid programs,…
Read More